Extended Data Fig. 4: Change in EORTC QLQ-C30 Global Health Score over time. | Nature Medicine

Extended Data Fig. 4: Change in EORTC QLQ-C30 Global Health Score over time.

From: Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

Extended Data Fig. 4: Change in EORTC QLQ-C30 Global Health Score over time.The alternative text for this image may have been generated using AI.

Patients were surveyed at 6-week intervals from baseline (censored at week 60 due to small number of responses (<5)). Data are presented as mean values ± 95% CI. Mean change from baseline was compared to established levels of MCID1 improvement or deterioration. A number of responses (n) at each timepoint are displayed in the data table (range per treatment arm, 6–20). CI, confidence interval; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer’s Core Quality of Life Questionnaire; MCID, minimum clinically important difference.

Back to article page